INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29701, 28577, 'Trospium', 'Kidney Diseases', 'Trospium is known to be substantially excreted by the kidney, and the risk of adverse reactions may be greater in patients with impaired renal function.  The use of trospium is not recommended in patients with severe renal impairment (creatinine clearance less than 30 mL/minute).  Caution is recommended when using this agent in patients with creatinine clearance ranging from 30 to 80 mL/min as the pharmacokinetics of trospium have not been studied in patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29702, 28578, 'Trospium', 'Kidney Diseases', 'Trospium is known to be substantially excreted by the kidney, and the risk of adverse reactions may be greater in patients with impaired renal function.  The use of trospium is not recommended in patients with severe renal impairment (creatinine clearance less than 30 mL/minute).  Caution is recommended when using this agent in patients with creatinine clearance ranging from 30 to 80 mL/min as the pharmacokinetics of trospium have not been studied in patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29703, 3454, 'Tropicamide (ophthalmic)', 'Glaucoma', 'Anticholinergic agents are contraindicated in patients with primary glaucoma, a tendency toward glaucoma (narrow anterior chamber angle), or adhesions (synechiae) between the iris and lens, as well as for the elderly and others in whom undiagnosed glaucoma or excessive pressure in the eye may be present.  Because anticholinergics cause mydriasis, they may exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29704, 7851, 'Tropicamide (ophthalmic)', 'Glaucoma', 'Anticholinergic agents are contraindicated in patients with primary glaucoma, a tendency toward glaucoma (narrow anterior chamber angle), or adhesions (synechiae) between the iris and lens, as well as for the elderly and others in whom undiagnosed glaucoma or excessive pressure in the eye may be present.  Because anticholinergics cause mydriasis, they may exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29705, 8491, 'Tropicamide (ophthalmic)', 'Glaucoma', 'Anticholinergic agents are contraindicated in patients with primary glaucoma, a tendency toward glaucoma (narrow anterior chamber angle), or adhesions (synechiae) between the iris and lens, as well as for the elderly and others in whom undiagnosed glaucoma or excessive pressure in the eye may be present.  Because anticholinergics cause mydriasis, they may exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29706, 23163, 'Tropicamide (ophthalmic)', 'Glaucoma', 'Anticholinergic agents are contraindicated in patients with primary glaucoma, a tendency toward glaucoma (narrow anterior chamber angle), or adhesions (synechiae) between the iris and lens, as well as for the elderly and others in whom undiagnosed glaucoma or excessive pressure in the eye may be present.  Because anticholinergics cause mydriasis, they may exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29707, 23990, 'Tropicamide (ophthalmic)', 'Glaucoma', 'Anticholinergic agents are contraindicated in patients with primary glaucoma, a tendency toward glaucoma (narrow anterior chamber angle), or adhesions (synechiae) between the iris and lens, as well as for the elderly and others in whom undiagnosed glaucoma or excessive pressure in the eye may be present.  Because anticholinergics cause mydriasis, they may exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29708, 30964, 'Tropicamide (ophthalmic)', 'Glaucoma', 'Anticholinergic agents are contraindicated in patients with primary glaucoma, a tendency toward glaucoma (narrow anterior chamber angle), or adhesions (synechiae) between the iris and lens, as well as for the elderly and others in whom undiagnosed glaucoma or excessive pressure in the eye may be present.  Because anticholinergics cause mydriasis, they may exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29709, 30965, 'Tropicamide (ophthalmic)', 'Glaucoma', 'Anticholinergic agents are contraindicated in patients with primary glaucoma, a tendency toward glaucoma (narrow anterior chamber angle), or adhesions (synechiae) between the iris and lens, as well as for the elderly and others in whom undiagnosed glaucoma or excessive pressure in the eye may be present.  Because anticholinergics cause mydriasis, they may exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29710, 33807, 'Tropicamide (ophthalmic)', 'Glaucoma', 'Anticholinergic agents are contraindicated in patients with primary glaucoma, a tendency toward glaucoma (narrow anterior chamber angle), or adhesions (synechiae) between the iris and lens, as well as for the elderly and others in whom undiagnosed glaucoma or excessive pressure in the eye may be present.  Because anticholinergics cause mydriasis, they may exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29711, 0, 'Trioxsalen', 'Photosensitivity Disorders', 'The use of trioxsalen is contraindicated in patients with disease states associated with photosensitivity, such as porphyria, acute lupus erythematosus, or leukoderma of infectious origin.  Trioxsalen may cause an exacerbation of these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29712, 27251, 'Tromethamine', 'Acidosis, Respiratory', 'The use of tromethamine is contraindicated in patients with chronic respiratory acidosis.  Tromethamine decreases carbon dioxide tension resulting in depressed ventilation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29713, 27251, 'Tromethamine', 'Kidney Diseases', 'The use of tromethamine is contraindicated in patients with severe renal impairment (anuria, uremia) and should be administered with caution in patients with renal dysfunction.  Tromethamine may accumulate in patients with renal impairment as it is not appreciably metabolized and is primarily eliminated by the kidney.  Hyperkalemia may result due to tromethamine use in patients with compromised renal function.  Clinical monitoring of renal function and electrolyte levels is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29714, 27251, 'Tromethamine', 'Acid-Base Imbalance', 'Alkalinizing agents act as proton acceptors and/or dissociate to provide bicarbonate ions.  Elimination of bicarbonate is decreased in patients with renal impairment and can result in metabolic alkalosis.  Symptoms of metabolic alkalosis include hyperirritability or tetany, arrhythmia, and/or seizures (altered pH = altered calcium), or lactic acidosis due to impaired oxygen release.  Therapy with alkalinizing agents should be administered with extreme caution in patients with compromised renal function.  Clinical monitoring of renal function, acid/base balance and electrolytes is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29715, 27251, 'Tromethamine', 'Hypoglycemia', 'Dose-related changes in blood glucose concentrations resulting in hypoglycemia have occurred during administration of tromethamine.  Rapid infusion of tromethamine has also resulted in prolonged hypoglycemia.  Therapy with tromethamine should be administered cautiously in patients with diabetes and temporary dosage modification of antihyperglycemic agents may be necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29716, 0, 'Benzylpenicillin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29717, 0, 'Benzylpenicillin', 'Asthma', 'Penicillin products should be used with caution in individuals with histories of significant allergies and/or asthma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29718, 20431, 'Trimipramine', 'Anticholinergic Syndrome', 'Tricyclic and tetracyclic antidepressants (TCAs) have anticholinergic activity, to which elderly patients are particularly sensitive.  Tertiary amines such as amitriptyline and trimipramine tend to exhibit greater anticholinergic effects than other agents in the class.  Therapy with TCAs should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.  In patients with angle-closure glaucoma, even average doses can precipitate an attack.  Glaucoma should be treated and under control prior to initiation of therapy with TCAs, and intraocular pressure monitored during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29719, 20431, 'Trimipramine', 'Cardiovascular Diseases', 'Tricyclic and tetracyclic antidepressants (TCAs) may cause orthostatic hypotension, reflex tachycardia, syncope, and dizziness, particularly during initiation of therapy or rapid escalation of dosage.  Imipramine appears to have the greatest propensity to induce these effects, while secondary amines such as nortriptyline may do so less frequently.  Tolerance to the hypotensive effects often develops after a few doses to a few weeks.  Rarely, collapse and sudden death have occurred secondary to severe hypotension.  Other reported adverse cardiovascular effects include tachycardia, arrhythmias, heart block, hypertension, thrombosis, thrombophlebitis, myocardial infarction, strokes, congestive heart failure, and ECG abnormalities such as PR and QT interval prolongation.  Therapy with TCAs should be avoided during the acute recovery phase following myocardial infarction, and should be administered only with extreme caution in patients with hyperthyroidism, a history of cardiovascular or cerebrovascular disease, or a predisposition to hypotension.  Close monitoring of cardiovascular status, including ECG changes, is recommended at all dosages.  Many of the newer antidepressants, including bupropion and the selective serotonin reuptake inhibitors (SSRIs), are considerably less or minimally cardiotoxic and may be appropriate alternatives.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29720, 20431, 'Trimipramine', 'Pheochromocytoma', 'Tricyclic and tetracyclic antidepressants (TCAs) may potentiate the effects of circulating catecholamines.  Enhanced sympathetic activity can provoke hypertensive crises in patients with pheochromocytoma or other tumors of the adrenal medulla, such as some neuroblastomas.  Therapy with TCAs should be administered cautiously in patients with these tumors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29721, 20431, 'Trimipramine', 'Acute Myocardial Infarction Recovery', 'The use of most tricyclic antidepressants is contraindicated in patients that are going through the acute recovery period after a myocardial infarction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29722, 20431, 'Trimipramine', 'Depressive Disorder', 'Adult and pediatric patients with depression may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29723, 20431, 'Trimipramine', 'Epilepsy', 'Tricyclic antidepressants (TCAs), can lower the seizure threshold and trigger seizures.  These drugs should be used with extreme caution in patients with a history of seizures, or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.  Daily dose restrictions might apply for specific antidepressants.  Physicians are encouraged to get additional dosing recommendations on the manufacturer''s prescribing information.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29724, 20431, 'Trimipramine', 'Bone Marrow Failure Disorders', 'The use of tricyclic and tetracyclic antidepressants (TCAs) has rarely been associated with bone marrow suppression.  Leukopenia, agranulocytosis, thrombocytopenia, anemia, eosinophilia, purpura, and pancytopenia have been reported with some TCAs.  Patients with preexisting bone marrow suppression or blood dyscrasias receiving TCAs should be monitored closely during therapy for further decreases in blood counts.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29725, 20431, 'Trimipramine', 'Diabetes Mellitus', 'Both elevation and lowering of blood sugar levels have been reported with the use of some tricyclic antidepressants (TCAs).  Rarely, these effects have also occurred with maprotiline, a tetracyclic antidepressant.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents, particularly during dosage escalation or whenever dosage has been altered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29726, 20431, 'Trimipramine', 'Liver Diseases', 'Tricyclic and tetracyclic antidepressants (TCAs) are known to undergo metabolism in the liver.  Some of the metabolites, such as those of imipramine, clomipramine and desipramine, may be pharmacologically active.  Many of the metabolites are also excreted by the kidney.  There are very limited data concerning the use of TCAs in patients with renal and/or liver disease.  Therapy with TCAs should be administered cautiously in patients with significantly impaired renal or hepatic function.  Dosage adjustments may be necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29727, 20431, 'Trimipramine', 'Schizophrenia', 'Tricyclic antidepressants (TCAs) may aggravate symptoms of psychosis in schizophrenic patients, particularly those with paranoid symptomatology.  Depressed patients, usually those with bipolar disorder, may experience a switch from depression to mania or hypomania.  These occurrences have also been reported rarely with the tetracyclic antidepressant, maprotiline.  Therapy with these agents should be administered cautiously in patients with schizophrenia, bipolar disorder, or a history of mania.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29728, 20431, 'Trimipramine', 'Tardive Dyskinesia', 'Tricyclic and tetracyclic antidepressants (TCAs) have anticholinergic activity, to which elderly patients are particularly sensitive.  Tertiary amines such as amitriptyline and trimipramine tend to exhibit greater anticholinergic effects than other agents in the class.  As with other drugs that possess anticholinergic activity, TCAs may aggravate tardive dyskinesia or induce previously suppressed symptoms.  Patients with tardive dyskinesia requiring therapy with TCAs should be monitored for exacerbation of the condition.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29729, 20431, 'Trimipramine', 'Alcoholic Intoxication', 'Tricyclic antidepressants can enhance the response to alcohol.  In patients who may use alcohol excessively, it should be borne in mind that the potentiation may increase the danger inherent in any suicide attempt or overdosage.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29730, 20431, 'Trimipramine', 'Bipolar Disorder', 'A major depressive episode can be the initial presentation of bipolar disorder.  Patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder prior to initiating treatment with a tricyclic antidepressant.  This screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression.  It should be noted that tricyclic antidepressants are not approved for use in treating bipolar depression.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29731, 20431, 'Trimipramine', 'Glaucoma', 'Tricyclic antidepressants as other type of antidepressants have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with anatomically narrow angle or history of glaucoma.  Doxepin hydrochloride capsules are contraindicated in patients with glaucoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29732, 20431, 'Trimipramine', 'Neutropenia', 'The use of some tricyclic antidepressants has been associated with neutropenia (ANC < 500/mm3) and agranulocytosis (ANC < 500/mm3).  Leukocyte and differential blood counts should be performed in patients that develop fever and sore throat during treatment.  Therapy should be discontinued if there is evidence of pathologic neutrophil depression.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29733, 20431, 'Trimipramine', 'Thyroid Diseases', 'Most tricyclic antidepressants should be administered with caution in hyperthyroid patients or those receiving thyroid medication as they may develop arrhythmias when these drugs are given.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29734, 20431, 'Trimipramine', 'Urinary Retention', 'Due to their anticholinergic properties, tricyclic antidepressants should be administered with caution in patients with history of urinary retention.  Particularly doxepin hydrochloride capsules are contraindicated in patients with tendency to urinary retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29735, 0, 'Tucatinib', 'Hepatic Insufficiency', 'Tucatinib is an hepatotoxic drug.  Additionally, its exposure is increased in patients with severe hepatic impairment, reason why the dosage has to be reduced in these patients (Child-Pugh C).  Consult the manufacturers prescribing information for details on dosage modification.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29736, 37, 'Acetylcysteine', 'Hepatic Encephalopathy', 'The use of acetylcysteine should be discontinued in patients with encephalopathy due to hepatic failure to avoid further administration of nitrogenous substances.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29737, 39, 'Acetylcysteine', 'Hepatic Encephalopathy', 'The use of acetylcysteine should be discontinued in patients with encephalopathy due to hepatic failure to avoid further administration of nitrogenous substances.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29738, 49, 'Acetylcysteine', 'Hepatic Encephalopathy', 'The use of acetylcysteine should be discontinued in patients with encephalopathy due to hepatic failure to avoid further administration of nitrogenous substances.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29739, 1642, 'Acetylcysteine', 'Hepatic Encephalopathy', 'The use of acetylcysteine should be discontinued in patients with encephalopathy due to hepatic failure to avoid further administration of nitrogenous substances.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29740, 1772, 'Acetylcysteine', 'Hepatic Encephalopathy', 'The use of acetylcysteine should be discontinued in patients with encephalopathy due to hepatic failure to avoid further administration of nitrogenous substances.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29741, 3383, 'Acetylcysteine', 'Hepatic Encephalopathy', 'The use of acetylcysteine should be discontinued in patients with encephalopathy due to hepatic failure to avoid further administration of nitrogenous substances.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29742, 5480, 'Acetylcysteine', 'Hepatic Encephalopathy', 'The use of acetylcysteine should be discontinued in patients with encephalopathy due to hepatic failure to avoid further administration of nitrogenous substances.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29743, 5545, 'Acetylcysteine', 'Hepatic Encephalopathy', 'The use of acetylcysteine should be discontinued in patients with encephalopathy due to hepatic failure to avoid further administration of nitrogenous substances.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29744, 12631, 'Acetylcysteine', 'Hepatic Encephalopathy', 'The use of acetylcysteine should be discontinued in patients with encephalopathy due to hepatic failure to avoid further administration of nitrogenous substances.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29745, 13314, 'Acetylcysteine', 'Hepatic Encephalopathy', 'The use of acetylcysteine should be discontinued in patients with encephalopathy due to hepatic failure to avoid further administration of nitrogenous substances.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29746, 13328, 'Acetylcysteine', 'Hepatic Encephalopathy', 'The use of acetylcysteine should be discontinued in patients with encephalopathy due to hepatic failure to avoid further administration of nitrogenous substances.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29747, 19211, 'Acetylcysteine', 'Hepatic Encephalopathy', 'The use of acetylcysteine should be discontinued in patients with encephalopathy due to hepatic failure to avoid further administration of nitrogenous substances.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29748, 19212, 'Acetylcysteine', 'Hepatic Encephalopathy', 'The use of acetylcysteine should be discontinued in patients with encephalopathy due to hepatic failure to avoid further administration of nitrogenous substances.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29749, 20473, 'Acetylcysteine', 'Hepatic Encephalopathy', 'The use of acetylcysteine should be discontinued in patients with encephalopathy due to hepatic failure to avoid further administration of nitrogenous substances.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29750, 23063, 'Acetylcysteine', 'Hepatic Encephalopathy', 'The use of acetylcysteine should be discontinued in patients with encephalopathy due to hepatic failure to avoid further administration of nitrogenous substances.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29751, 23070, 'Acetylcysteine', 'Hepatic Encephalopathy', 'The use of acetylcysteine should be discontinued in patients with encephalopathy due to hepatic failure to avoid further administration of nitrogenous substances.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29752, 26326, 'Acetylcysteine', 'Hepatic Encephalopathy', 'The use of acetylcysteine should be discontinued in patients with encephalopathy due to hepatic failure to avoid further administration of nitrogenous substances.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29753, 26327, 'Acetylcysteine', 'Hepatic Encephalopathy', 'The use of acetylcysteine should be discontinued in patients with encephalopathy due to hepatic failure to avoid further administration of nitrogenous substances.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29754, 27273, 'Acetylcysteine', 'Hepatic Encephalopathy', 'The use of acetylcysteine should be discontinued in patients with encephalopathy due to hepatic failure to avoid further administration of nitrogenous substances.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29755, 27676, 'Acetylcysteine', 'Hepatic Encephalopathy', 'The use of acetylcysteine should be discontinued in patients with encephalopathy due to hepatic failure to avoid further administration of nitrogenous substances.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29756, 30073, 'Acetylcysteine', 'Hepatic Encephalopathy', 'The use of acetylcysteine should be discontinued in patients with encephalopathy due to hepatic failure to avoid further administration of nitrogenous substances.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29757, 30074, 'Acetylcysteine', 'Hepatic Encephalopathy', 'The use of acetylcysteine should be discontinued in patients with encephalopathy due to hepatic failure to avoid further administration of nitrogenous substances.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29758, 30358, 'Acetylcysteine', 'Hepatic Encephalopathy', 'The use of acetylcysteine should be discontinued in patients with encephalopathy due to hepatic failure to avoid further administration of nitrogenous substances.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29759, 30588, 'Acetylcysteine', 'Hepatic Encephalopathy', 'The use of acetylcysteine should be discontinued in patients with encephalopathy due to hepatic failure to avoid further administration of nitrogenous substances.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29760, 30589, 'Acetylcysteine', 'Hepatic Encephalopathy', 'The use of acetylcysteine should be discontinued in patients with encephalopathy due to hepatic failure to avoid further administration of nitrogenous substances.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29761, 31259, 'Acetylcysteine', 'Hepatic Encephalopathy', 'The use of acetylcysteine should be discontinued in patients with encephalopathy due to hepatic failure to avoid further administration of nitrogenous substances.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29762, 32105, 'Acetylcysteine', 'Hepatic Encephalopathy', 'The use of acetylcysteine should be discontinued in patients with encephalopathy due to hepatic failure to avoid further administration of nitrogenous substances.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29763, 32683, 'Acetylcysteine', 'Hepatic Encephalopathy', 'The use of acetylcysteine should be discontinued in patients with encephalopathy due to hepatic failure to avoid further administration of nitrogenous substances.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29764, 37, 'Acetylcysteine', 'Asthma', 'Acetylcysteine should be used with caution in patients with asthma, or where there is a history of bronchospasm.  Patients with asthma should be closely monitored during the initiation of and throughout acetylcysteine therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29765, 39, 'Acetylcysteine', 'Asthma', 'Acetylcysteine should be used with caution in patients with asthma, or where there is a history of bronchospasm.  Patients with asthma should be closely monitored during the initiation of and throughout acetylcysteine therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29766, 49, 'Acetylcysteine', 'Asthma', 'Acetylcysteine should be used with caution in patients with asthma, or where there is a history of bronchospasm.  Patients with asthma should be closely monitored during the initiation of and throughout acetylcysteine therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29767, 1642, 'Acetylcysteine', 'Asthma', 'Acetylcysteine should be used with caution in patients with asthma, or where there is a history of bronchospasm.  Patients with asthma should be closely monitored during the initiation of and throughout acetylcysteine therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29768, 1772, 'Acetylcysteine', 'Asthma', 'Acetylcysteine should be used with caution in patients with asthma, or where there is a history of bronchospasm.  Patients with asthma should be closely monitored during the initiation of and throughout acetylcysteine therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29769, 3383, 'Acetylcysteine', 'Asthma', 'Acetylcysteine should be used with caution in patients with asthma, or where there is a history of bronchospasm.  Patients with asthma should be closely monitored during the initiation of and throughout acetylcysteine therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29770, 5480, 'Acetylcysteine', 'Asthma', 'Acetylcysteine should be used with caution in patients with asthma, or where there is a history of bronchospasm.  Patients with asthma should be closely monitored during the initiation of and throughout acetylcysteine therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29771, 5545, 'Acetylcysteine', 'Asthma', 'Acetylcysteine should be used with caution in patients with asthma, or where there is a history of bronchospasm.  Patients with asthma should be closely monitored during the initiation of and throughout acetylcysteine therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29772, 12631, 'Acetylcysteine', 'Asthma', 'Acetylcysteine should be used with caution in patients with asthma, or where there is a history of bronchospasm.  Patients with asthma should be closely monitored during the initiation of and throughout acetylcysteine therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29773, 13314, 'Acetylcysteine', 'Asthma', 'Acetylcysteine should be used with caution in patients with asthma, or where there is a history of bronchospasm.  Patients with asthma should be closely monitored during the initiation of and throughout acetylcysteine therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29774, 13328, 'Acetylcysteine', 'Asthma', 'Acetylcysteine should be used with caution in patients with asthma, or where there is a history of bronchospasm.  Patients with asthma should be closely monitored during the initiation of and throughout acetylcysteine therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29775, 19211, 'Acetylcysteine', 'Asthma', 'Acetylcysteine should be used with caution in patients with asthma, or where there is a history of bronchospasm.  Patients with asthma should be closely monitored during the initiation of and throughout acetylcysteine therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29776, 19212, 'Acetylcysteine', 'Asthma', 'Acetylcysteine should be used with caution in patients with asthma, or where there is a history of bronchospasm.  Patients with asthma should be closely monitored during the initiation of and throughout acetylcysteine therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29777, 20473, 'Acetylcysteine', 'Asthma', 'Acetylcysteine should be used with caution in patients with asthma, or where there is a history of bronchospasm.  Patients with asthma should be closely monitored during the initiation of and throughout acetylcysteine therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29778, 23063, 'Acetylcysteine', 'Asthma', 'Acetylcysteine should be used with caution in patients with asthma, or where there is a history of bronchospasm.  Patients with asthma should be closely monitored during the initiation of and throughout acetylcysteine therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29779, 23070, 'Acetylcysteine', 'Asthma', 'Acetylcysteine should be used with caution in patients with asthma, or where there is a history of bronchospasm.  Patients with asthma should be closely monitored during the initiation of and throughout acetylcysteine therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29780, 26326, 'Acetylcysteine', 'Asthma', 'Acetylcysteine should be used with caution in patients with asthma, or where there is a history of bronchospasm.  Patients with asthma should be closely monitored during the initiation of and throughout acetylcysteine therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29781, 26327, 'Acetylcysteine', 'Asthma', 'Acetylcysteine should be used with caution in patients with asthma, or where there is a history of bronchospasm.  Patients with asthma should be closely monitored during the initiation of and throughout acetylcysteine therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29782, 27273, 'Acetylcysteine', 'Asthma', 'Acetylcysteine should be used with caution in patients with asthma, or where there is a history of bronchospasm.  Patients with asthma should be closely monitored during the initiation of and throughout acetylcysteine therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29783, 27676, 'Acetylcysteine', 'Asthma', 'Acetylcysteine should be used with caution in patients with asthma, or where there is a history of bronchospasm.  Patients with asthma should be closely monitored during the initiation of and throughout acetylcysteine therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29784, 30073, 'Acetylcysteine', 'Asthma', 'Acetylcysteine should be used with caution in patients with asthma, or where there is a history of bronchospasm.  Patients with asthma should be closely monitored during the initiation of and throughout acetylcysteine therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29785, 30074, 'Acetylcysteine', 'Asthma', 'Acetylcysteine should be used with caution in patients with asthma, or where there is a history of bronchospasm.  Patients with asthma should be closely monitored during the initiation of and throughout acetylcysteine therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29786, 30358, 'Acetylcysteine', 'Asthma', 'Acetylcysteine should be used with caution in patients with asthma, or where there is a history of bronchospasm.  Patients with asthma should be closely monitored during the initiation of and throughout acetylcysteine therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29787, 30588, 'Acetylcysteine', 'Asthma', 'Acetylcysteine should be used with caution in patients with asthma, or where there is a history of bronchospasm.  Patients with asthma should be closely monitored during the initiation of and throughout acetylcysteine therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29788, 30589, 'Acetylcysteine', 'Asthma', 'Acetylcysteine should be used with caution in patients with asthma, or where there is a history of bronchospasm.  Patients with asthma should be closely monitored during the initiation of and throughout acetylcysteine therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29789, 31259, 'Acetylcysteine', 'Asthma', 'Acetylcysteine should be used with caution in patients with asthma, or where there is a history of bronchospasm.  Patients with asthma should be closely monitored during the initiation of and throughout acetylcysteine therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29790, 32105, 'Acetylcysteine', 'Asthma', 'Acetylcysteine should be used with caution in patients with asthma, or where there is a history of bronchospasm.  Patients with asthma should be closely monitored during the initiation of and throughout acetylcysteine therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29791, 32683, 'Acetylcysteine', 'Asthma', 'Acetylcysteine should be used with caution in patients with asthma, or where there is a history of bronchospasm.  Patients with asthma should be closely monitored during the initiation of and throughout acetylcysteine therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29792, 37, 'Acetylcysteine', 'Dehydration', 'Intravenous administration of acetylcysteine can cause fluid overload, potentially resulting in hyponatremia, seizure and death.  To avoid fluid overload, a diluted dose is recommended, especially in patients less than 40 kg and those requiring fluid restrictions (see dosage and administration recommended by manufacturers).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29793, 39, 'Acetylcysteine', 'Dehydration', 'Intravenous administration of acetylcysteine can cause fluid overload, potentially resulting in hyponatremia, seizure and death.  To avoid fluid overload, a diluted dose is recommended, especially in patients less than 40 kg and those requiring fluid restrictions (see dosage and administration recommended by manufacturers).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29794, 49, 'Acetylcysteine', 'Dehydration', 'Intravenous administration of acetylcysteine can cause fluid overload, potentially resulting in hyponatremia, seizure and death.  To avoid fluid overload, a diluted dose is recommended, especially in patients less than 40 kg and those requiring fluid restrictions (see dosage and administration recommended by manufacturers).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29795, 1642, 'Acetylcysteine', 'Dehydration', 'Intravenous administration of acetylcysteine can cause fluid overload, potentially resulting in hyponatremia, seizure and death.  To avoid fluid overload, a diluted dose is recommended, especially in patients less than 40 kg and those requiring fluid restrictions (see dosage and administration recommended by manufacturers).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29796, 1772, 'Acetylcysteine', 'Dehydration', 'Intravenous administration of acetylcysteine can cause fluid overload, potentially resulting in hyponatremia, seizure and death.  To avoid fluid overload, a diluted dose is recommended, especially in patients less than 40 kg and those requiring fluid restrictions (see dosage and administration recommended by manufacturers).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29797, 3383, 'Acetylcysteine', 'Dehydration', 'Intravenous administration of acetylcysteine can cause fluid overload, potentially resulting in hyponatremia, seizure and death.  To avoid fluid overload, a diluted dose is recommended, especially in patients less than 40 kg and those requiring fluid restrictions (see dosage and administration recommended by manufacturers).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29798, 5480, 'Acetylcysteine', 'Dehydration', 'Intravenous administration of acetylcysteine can cause fluid overload, potentially resulting in hyponatremia, seizure and death.  To avoid fluid overload, a diluted dose is recommended, especially in patients less than 40 kg and those requiring fluid restrictions (see dosage and administration recommended by manufacturers).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29799, 5545, 'Acetylcysteine', 'Dehydration', 'Intravenous administration of acetylcysteine can cause fluid overload, potentially resulting in hyponatremia, seizure and death.  To avoid fluid overload, a diluted dose is recommended, especially in patients less than 40 kg and those requiring fluid restrictions (see dosage and administration recommended by manufacturers).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29800, 12631, 'Acetylcysteine', 'Dehydration', 'Intravenous administration of acetylcysteine can cause fluid overload, potentially resulting in hyponatremia, seizure and death.  To avoid fluid overload, a diluted dose is recommended, especially in patients less than 40 kg and those requiring fluid restrictions (see dosage and administration recommended by manufacturers).', '2', '', 'DDInter', 0);
